Impact of safety warnings on antipsychotic prescriptions in dementia: Nothing has changed but the years and the substances

European Neuropsychopharmacology

Volumn 23, Issue 9, 2013, Pages 1034-1042

  Schulze, Jana ^a   van den Bussche, Hendrik ^b   Glaeske, Gerd ^a   Kaduszkiewicz, Hanna ^b   Wiese, Birgitt ^c   Hoffmann, Falk ^a  

^a UNIVERSITY OF BREMEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antipsychotic agents; Dementia; Germany; Health services research; Prescription trends

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENPERIDOL; BROMPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERAZINE; PERPHENAZINE; PIMOZIDE; PROMAZINE; PROMETHAZINE; PROTHIPENDYL; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

AGE DISTRIBUTION; AGED; ARTICLE; DEMENTIA; DEMOGRAPHY; DRUG PACKAGING; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; SEX RATIO; TREND STUDY;

ANTIPSYCHOTIC AGENTS; DEMENTIA; GERMANY; HEALTH SERVICES RESEARCH; PRESCRIPTION TRENDS;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; DEMENTIA; DRUG LABELING; FEMALE; GERMANY; HUMANS; INSURANCE, HEALTH; MALE;

EID: 84884207245     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.02.001     Document Type: Article

References (49)

1. a-t-arznei-telegramm, 2002. Schlaganfall, TIA und Tod unter Risperidon (Risperdal) im Alter. a-t. 33: 130.
2. AVP-Arzneiverordnung in der Praxis, 2004. Therapieempfehlung der Arzneimittelkommission der deutschen Ärzteschaft. Demenz. http://www.akdae.de/Arzneimitteltherapie/TE/A-Z/PDF/Demenz.pdf#page=1&view=fitB.
3. Azermai M., Petrovic M., Elseviers M.M., Bourgeois J., Van Bortel L.M., Vander Stichele R.H. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res. Rev. 2012, 11:78-86.
4. Ballard C., Day S., Sharp S., Wing G., Sorensen S. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int. Rev. Psychiatry 2008, 20:396-404.
5. Ballard C., Hanney M.L., Theodoulou M., Douglas S., McShane R., Kossakowski K., Gill R., Juszczak E., Yu L.M., Jacoby R. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009, 8:151-157.
6. Ballard C., Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat. Rev. Neurosci. 2006, 7:492-500.
7. Ballard C.G., Waite J., Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst. Rev. 2006, 1:CD003476.
8. Cerejeira J., Lagarto L., Mukaetova-Ladinska E.B. Behavioral and psychological symptoms of dementia. Front. Neurol 2012, 3:73.
9. DEGAM-Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin, 2008. DEGAM - Leitlinie Nr. 12: Demenz. http://www.leitlinien.degam.de/uploads/media/LL-12_Langfassung_TJ_03_korr_01.pdf.
10. DGPPN and DGN-Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde; Deutsche Gesellschaft für Neurologie, 2009. S3-Leitlinie "Demenzen" Langversion 2009. http://www.dggpp.de/documents/s3leitlinie-demenz-kf.pdf.
11. Dorsey E.R., Rabbani A., Gallagher S.A., Conti R.M., Alexander G.C. Impact of FDA black box advisory on antipsychotic medication use. Arch. Intern. Med. 2010, 170:96-103.
12. Dusetzina S.B., Higashi A.S., Dorsey E.R., Conti R., Huskamp H.A., Zhu S., Garfield C.F., Alexander G.C. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med. Care 2012, 50:466-478.
13. Eisele M., van den Bussche H., Koller D., Wiese B., Kaduszkiewicz H., Maier W., Glaeske G., Steinmann S., Wegscheider K., Schön G. Utilization patterns of ambulatory medical care before and after the diagnosis of dementia in Germany-results of a case-control study. Dement. Geriatr. Cogn. Disord. 2010, 29:475-483.
14. EMA-European Medicines Agency, 2008. Opinion of the Committee for medicinal products for human use pursuant to article 5(3) of regulation (EC) No 726/2004, on conventional antipsychotics. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500054056.pdf.
15. FDA-U.S. Food and Drug Administration, 2008. FDA ALERT. Information for healthcare professionals: conventional antipsychotics. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm.
16. FDA-U.S. Food and Drug Administration, 2005. Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM053171.
17. Fernandez M., Gobartt A., Balana M. Behavioural symptoms in patients with AlzheimerD́s disease and their association with cognitive impairment. BMC Neurol. 2010, 10:87.
18. Finkel S.I., Silva E., Cohen J.C., Miller G., Sartorius S., N. Consensus statement. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int. Psychogeratr. 1996, 8(Suppl. 3):497-500.
19. Franchi C., Tettamanti M., Marengoni A., Bonometti F., Pasina L., Cortesi L., Fortino I., Bortolotti A., Merlino L., Lucca U., Riva E., Nobili A. Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. Eur. Neuropsychopharmacol. 2012, 22:569-577.
20. Guthrie B., Clark S.A., McCowan C. The burden of psychotropic drug prescribing in people with dementia: a population database study. Age Ageing 2010, 39:637-642.
21. Health Canada, Health Products and Food Branch, 2002. Important Drug Safety Information. RISPERDAL* (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/risperdal_hpc-cps-eng.pdf.
22. Hoffmann F., Icks A. Diabetes prevalence based on health insurance claims: large differences between companies. Diabet. Med. 2011, 28:919-923.
23. Hoffmann F., Icks A. Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor. Gesundheitswesen 2012, 74:291-297.
24. Hoffmann F., van den Bussche H., Glaeske G., Kaduszkiewicz H. Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. Int. Clin. Psychopharmacol. 2010, 25:29-36.
25. Hoffmann F., van den Bussche H., Wiese B., Schön G., Koller D., Eisele M., Glaeske G., Scherer M., Kaduszkiewicz H. Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. BMC Psychiatry 2011, 11:190.
26. Huybrechts K.F., Gerhard T., Crystal S., Olfson M., Avorn J., Levin R., Lucas J.A., Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population-based cohort study. BMJ 2012, 23:e977.
27. Janssen-Cilag GmbH, 2004. Risperdal - Änderung der Produktinformation. Rote-Hand-Brief vom März 2004. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2004/84_20040308.pdf.
28. Kales H.C., Zivin K., Kim H.M., Valenstein M., Chiang C., Ignacio R.V., Ganoczy D., Cunningham F., Schneider L.S., Blow F.C. Trends in antipsychotic use in dementia 1999-2007. Arch. Gen. Psychiatry 2011, 68:190-197.
29. Kolanowski A., Fick D., Waller J.L., Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch. Psychiatr. Nurs. 2006, 20:217-225.
30. Laitinen M.L., Bell J.S., Lavikainen P., Lönnroos E., Sulkava R., Hartikainen S. Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. Int. Psychogeriatr. 2011, 23:1623-1631.
31. Lilly Pharma, 2004. Wichtige Information zu Olanzapin und zum Mortalitäts- und Schlaganfallrisiko bei älteren Patienten mit Demenz-assoziierter Psychose und/oder Verhaltensstörungen. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2004/85_20040308.pdf.
32. Lohse M.J., Lorenzen A., Müller-Oerlinghausen B. Psychopharmaka. Arzneiverordnungs-Report 2006, 819-868. Springer Verlag, Berlin, Heidelberg. U. Schwabe, D. Paffrath (Eds.).
33. Lyketsos C.G., Steinberg M., Tschanz J.T., Norton M.C., Steffens D.C., Breitner J.C. Mental and behavioural disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry 2000, 157:708-714.
34. Majic T., Pluta J.P., Mell T., Aichberger M.C., Treusch Y., Gutzmann H., Heinz A., Rapp M.A. The pharmacotherapy of neuropsychiatric symptoms of dementia: a cross-sectional study in 18 homes for the elderly in Berlin. Dtsch. Arztebl. Int. 2010, 107:320-327.
35. NICE-National Institute for Health and Clinical Excellence-Social Care Institute for Excellence, 2011. Dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. http://www.nice.org.uk/nicemedia/live/10998/30318/30318.pdf.
36. Rhee Y.J., Csernansky J.G., Emanuel L.L., Chang C.G., Shega J.W. Psychotropic medication burden and factors associated with antipsychotic use: analysis of a population-based sample of community-dwelling older persons with dementia. J. Am. Geriatr. Soc. 2011, 59:2100-2107.
37. Richter T., Meyer G., Möhler R., Köpke S. Psychosocial interventions for reducing antipsychotic medication in care home residents. Cochrane Database Syst. Rev. 2012, 12:CD008634. 10.1002/14651858.CD008634.pub2.
38. Riedel-Heller S.G., Busse A., Angermeyer M.C. Are cognitively impaired individuals adequately represented in community surveys? Recruitment challenges and strategies to facilitate participation in community surveys of older adults. A review. Eur. J. Epidemiol 2000, 16:827-835.
39. Schneider L.S., Dagerman K., Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Psychiatry 2006, 14:191-210.
40. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294:1934-1943.
41. Schneider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., Lebowitz B.D., Lyketsos C.G., Ryan J.M., Stroup T.S., Sultzer D.L., Weintraub D., Lieberman J.A., CATIE-AD Study Group Effectiveness of atypical antipsychotic drugs in patients with alzheimerD́s disease. N. Engl. J. Med. 2006, 355:1525-1538.
42. Sieberer, M., 2009. Antidepressiva und Neuroleptika bei älteren Menschen mit Demenzerkrankungen In: Glaeske, G., Schicktanz, C., Janhsen, K. (Eds.), GEK-Arzneimittel-Report 2009. Auswertungsergebnisse der GEK-Arzneimitteldaten aus den Jahren 2007 bis 2008. Asgard-Verlag, St. Augustin, pp. 136-148.
43. Sink K.M., Holden K.F., Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 2005, 293:596-608.
44. Steele C., Rovner B., Chase G.A., Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am. J. Psychiatry 1990, 147:1049-1051.
45. Steinberg M., Sheppard J.M., Tschanz J.T., Norton M.C., Steffens D.C., Breitner J.C.S., Lyketsos C.G. The incidence of mental and behavioral disturbances in dementia: The Cache County Study. J. Neuropsychiatry Clin. Neurosci. 2003, 15:340-345.
46. Valiyeva E., Herrmann N., Rochon P.A., Gill S.S., Anderson G.M. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008, 179:438-446.
47. WHO-World Health Organization, 2009. WHO Collaboration Center for Drug Statistics and Methodology. Definition and general considerations. Definition and introduction. http://www.whocc.no/ddd/definition_and_general_considera/.
48. WHO-World Health Organization, 2012. Alzheimer's Disease International. Dementia: a public health priority. http://whqlibdoc.who.int/publications/2012/9789241564458_eng.pdf.
49. Wolter D.K. Risiken von Antipsychotika im Alter, speziell bei Demenzen. Eine Übersicht. Z. Gerontopsychol. Psychiatr. 2009, 22:17-56.